Pilot clinical and validation study of the PROPKD score in clinical practice amongst patients with Autosomal Dominant Polycystic Kidney Disease
Journal Contribution ResearchOnline@JCUAbstract
[Extract] Worldwide, Autosomal Dominant Polycystic Kidney Disease (ADPKD) affects approximately 4–7 million individuals and accounts for 10% of patients receiving renal replacement therapy. Recently, the PROPKD score was developed from the GENKYST cohort to stratify risk of progression to end-stage kidney disease (ESKD) in patients with ADPKD, based on gender, hypertension <35 years, urological event <35 years and causative PKD1 or PKD2 genotype. The PROPKD score showed significant differences in kidney survival between ADPKD patients who were low risk (0–3 points), intermediate risk (4–6 points) and high risk (>6 points) in terms of progression to ESKD.
Journal
Nephrology
Publication Name
N/A
Volume
25
ISBN/ISSN
1440-1797
Edition
N/A
Issue
2
Pages Count
2
Location
N/A
Publisher
Wiley-Blackwell Publishing Asia
Publisher Url
N/A
Publisher Location
N/A
Publish Date
N/A
Url
N/A
Date
N/A
EISSN
N/A
DOI
10.1111/nep.13640